Irina Antonijevic MD, PhD

Irina Antonijevic, MD, PhD Medical Director, 609-945-9054 Irina brings more than 18 years of neuroscience research, with hands-on experience in both basic and clinical academic research, clinical practice and R&D in the pharmaceutical industry. Her work has focused on affective, inflammatory and neurodegenerative aspects of CNS disorders and has included neuroendocrine, electrophysiological and molecular markers in vivo (humans and rodents), ex vivo (human leukocytes) and in vitro. Before joining CHDI, Irina was Director Translational Research at Lundbeck Research USA, where she implemented a translational research strategy that used human blood transcription profiles to identify diagnostic subgroups of CNS disorders and distinct treatment responses and new drug targets based on improved molecular understanding of CNS disorders.

She also built an academic and regulatory network to support the translational biomarker efforts. Irina has also worked as a Core Clinician in traditional clinical development at Schering AG (now Bayer-Schering-Pharma), managing clinical development trials in neurology (mainly multiple sclerosis, including a pediatric study) and supporting clinical biomarker research.